METADATE CD
Clinical safety rating: caution
Comprehensive clinical and safety monograph for METADATE CD (METADATE CD).
Methylphenidate is a central nervous system (CNS) stimulant. It blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space. The precise mechanism for treating ADHD is not fully understood.
| Metabolism | Primarily hepatic via carboxylesterase CES1A1 to the inactive metabolite ritalinic acid; minor pathways include hydroxylation (CYP2D6) and microsomal oxidation. |
| Excretion | Renal: 78-97% as metabolites (primarily ritalinic acid), unchanged drug <1%; fecal: <2% |
| Half-life | Terminal elimination half-life: 6.8 hours (range 4.5-10.3 hours) for methylphenidate; clinical context: supports twice-daily dosing regimen |
| Protein binding | Methylphenidate: 10-33% bound to albumin; low binding, minimal displacement interactions |
| Volume of Distribution | Volume of distribution: 0.2-0.5 L/kg; indicates distribution into total body water and tissues |
| Bioavailability | Oral (extended-release): approximately 30% (range 11-52%) due to first-pass metabolism |
| Onset of Action | Oral (extended-release): 1-2 hours for peak plasma concentration; clinical effect observed within 1 hour |
| Duration of Action | Duration of clinical effect: 10-12 hours for the extended-release formulation; designed to cover the school day with a single morning dose |
20-60 mg orally once daily in the morning
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | No specific dose adjustment available; use with caution in severe renal impairment (GFR <30 mL/min) |
| Liver impairment | No specific dose adjustment for Child-Pugh; however, caution in severe hepatic impairment |
| Pediatric use | For ADHD in children ≥6 years: starting dose 20 mg once daily, titrated by 20 mg/week to max 60 mg/day |
| Geriatric use | Limited data; start at lower end of dosing range (20 mg daily) and monitor closely for adverse effects |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for METADATE CD (METADATE CD).
| Breastfeeding | Contraindicated due to methylphenidate excretion in breast milk. M/P ratio unknown; potential for infant stimulation, insomnia, and decreased appetite. Use alternative if breastfeeding. |
| Teratogenic Risk | Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal malformations (e.g., cardiac, skeletal) at high doses. Second and third trimesters: Risk of preterm birth, low birth weight, and neonatal withdrawal (tachycardia, irritability). |
| Fetal Monitoring |
■ FDA Black Box Warning
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including METADATE CD, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
| Serious Effects |
["Hypersensitivity to methylphenidate or any component of the product","Concurrent treatment with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI","Glaucoma","Tics or family history of Tourette's syndrome","Severe anxiety, tension, or agitation","Thyrotoxicosis","Hypertension (severe)"]
| Precautions | ["Abuse and dependence","Serious cardiovascular events (sudden death, stroke, MI) in patients with structural cardiac abnormalities or other serious heart problems","Blood pressure and heart rate increase","Psychiatric adverse events (exacerbation of psychosis, mania, aggression)","Long-term suppression of growth in children","Seizures (may lower seizure threshold)","Peripheral vasculopathy including Raynaud's phenomenon","Visual disturbances (difficulty with accommodation, blurred vision)","Hematologic effects (leukopenia, anemia, thrombocytopenia)"] |
Loading safety data…
| Monitor maternal blood pressure, heart rate, and weight gain. Fetal ultrasound for growth and anomalies. Neonatal monitoring for withdrawal symptoms and cardiovascular effects post-delivery. |
| Fertility Effects | No specific human data on fertility impairment. Animal studies show decreased implantation and increased fetal resorption at high doses. Caution in women planning pregnancy. |